NCT05131971View on ClinicalTrials.gov

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (PD) of GSK3888130B in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

54

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

October 12, 2023

Study Completion Date

October 12, 2023

Conditions

Multiple SclerosisColitis, Ulcerative

Interventions

DRUG

GSK3888130B

GSK3888130B will be administered.

DRUG

Placebo

Placebo will be administered.

Trial Locations (1)

CB2 2GG

GSK Investigational Site, Cambridge

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT05131971 - A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (PD) of GSK3888130B in Healthy Participants | Biotech Hunter | Biotech Hunter